Literature DB >> 32369506

Sex-specific cardiac remodeling in early and advanced stages of hypertrophic cardiomyopathy.

Louise L A M Nijenkamp1, Ilse A E Bollen1, Hans W M Niessen2, Cris G Dos Remedios3, Michelle Michels4, Corrado Poggesi5, Carolyn Y Ho6, Diederik W D Kuster1,7, Jolanda van der Velden1,7.   

Abstract

Hypertrophic cardiomyopathy (HCM) is the most frequent genetic cardiac disease with a prevalence of 1:500 to 1:200. While most patients show obstructive HCM and a relatively stable clinical phenotype (stage II), a small group of patients progresses to end-stage HCM (stage IV) within a relatively brief period. Previous research has shown sex-differences in stage II HCM with more diastolic dysfunction in female than in male patients. Moreover, female patients more often show progression to heart failure. Here we investigated if differences in functional and structural properties of the heart may underlie sex-differences in disease progression from stage II to stage IV HCM. Cardiac tissue from stage II and IV patients was obtained during myectomy (n = 54) and heart transplantation (n = 10), respectively. Isometric force was measured in membrane-permeabilized cardiomyocytes to define active and passive myofilament force development. Titin isoform composition was assessed using gel electrophoresis, and the amount of fibrosis and capillary density were determined with histology. In accordance with disease stage-dependent adverse cardiac remodeling end-stage patients showed a thinner interventricular septal wall and larger left ventricular and atrial diameters compared to stage II patients. Cardiomyocyte contractile properties and fibrosis were comparable between stage II and IV, while capillary density was significantly lower in stage IV compared to stage II. Women showed more adverse cellular remodeling compared to men at stage II, evident from more compliant titin, more fibrosis and lower capillary density. However, the disease stage-dependent reduction in capillary density was largest in men. In conclusion, the more severe cellular remodeling in female compared to male stage II patients suggests a more advanced disease stage at the time of myectomy in women. Changes in cardiomyocyte contractile properties do not explain the progression of stage II to stage IV, while reduced capillary density may underlie disease progression to end-stage heart failure.

Entities:  

Year:  2020        PMID: 32369506     DOI: 10.1371/journal.pone.0232427

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  8 in total

1.  Cardiac myosin binding protein-C variants in paediatric-onset hypertrophic cardiomyopathy: natural history and clinical outcomes.

Authors:  Ella Field; Gabrielle Norrish; Vanessa Acquaah; Kathleen Dady; Marcos Nicolas Cicerchia; Juan Pablo Ochoa; Petros Syrris; Karen McLeod; Ruth McGowan; Hannah Fell; Luis R Lopes; Elena Cervi; Juan Pablo Pablo Kaski
Journal:  J Med Genet       Date:  2021-08-16       Impact factor: 5.941

2.  Sex-related differences in left ventricular remodeling and outcome after alcohol septal ablation in hypertrophic obstructive cardiomyopathy: insights from cardiovascular magnetic resonance imaging.

Authors:  You-Zhou Chen; Xing-Shan Zhao; Jian-Song Yuan; Yan Zhang; Wei Liu; Shu-Bin Qiao
Journal:  Biol Sex Differ       Date:  2022-07-07       Impact factor: 8.811

3.  Molecular Genetic Basis of Hypertrophic Cardiomyopathy.

Authors:  A J Marian
Journal:  Circ Res       Date:  2021-05-13       Impact factor: 17.367

4.  Embryonic Onset of Sexually Dimorphic Heart Rates in the Viviparous Fish, Gambusia holbrooki.

Authors:  Seyed Ehsan Mousavi; G John Purser; Jawahar G Patil
Journal:  Biomedicines       Date:  2021-02-08

5.  Multi-omics integration identifies key upstream regulators of pathomechanisms in hypertrophic cardiomyopathy due to truncating MYBPC3 mutations.

Authors:  J Pei; M Schuldt; E Nagyova; J van der Velden; F W Asselbergs; M Harakalova; Z Gu; S El Bouhaddani; L Yiangou; M Jansen; J J A Calis; L M Dorsch; C Snijders Blok; N A M van den Dungen; N Lansu; B J Boukens; I R Efimov; M Michels; M C Verhaar; R de Weger; A Vink; F G van Steenbeek; A F Baas; R P Davis; H W Uh; D W D Kuster; C Cheng; M Mokry
Journal:  Clin Epigenetics       Date:  2021-03-23       Impact factor: 6.551

Review 6.  A framework for developing sex-specific engineered heart models.

Authors:  Roberta Lock; Hadel Al Asafen; Sharon Fleischer; Manuel Tamargo; Yimu Zhao; Milica Radisic; Gordana Vunjak-Novakovic
Journal:  Nat Rev Mater       Date:  2021-10-20       Impact factor: 76.679

Review 7.  Sex-Related Differences in Genetic Cardiomyopathies.

Authors:  Alessia Argirò; Carolyn Ho; Sharlene M Day; Jolanda van der Velden; Elisabetta Cerbai; Sara Saberi; Jil C Tardiff; Neal K Lakdawala; Iacopo Olivotto
Journal:  J Am Heart Assoc       Date:  2022-04-26       Impact factor: 6.106

8.  Myocardial contrast echocardiography assessment of perfusion abnormalities in hypertrophic cardiomyopathy.

Authors:  Paola Roldan; Sriram Ravi; James Hodovan; J Todd Belcik; Stephen B Heitner; Ahmad Masri; Jonathan R Lindner
Journal:  Cardiovasc Ultrasound       Date:  2022-09-19       Impact factor: 2.263

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.